Cost-Effectiveness of Transfusion of Platelet Components Prepared with Pathogen Inactivation Treatment in the United States

Clinical Therapeutics

Volumn 25, Issue 9, 2003, Pages 2464-2486

  Bell, Christopher F ^a   Botteman, Marc F ^a   Gao, Xin ^a   Weissfeld, Joel L ^b   Postma, Maarten J ^c   Pashos, Chris L ^a   Triulzi, Darrell ^b   Staginnus, Ulf ^d  

^a ABT ASSOCIATES   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c UNIVERSITY OF GRONINGEN   (Netherlands)

^d BAXTER HEALTHCARE CORPORATION   (United States)

Author keywords

Cost effectiveness; Pathogen inactivation; Platelet; Transfusion risks

Indexed keywords

ANTIBIOTIC AGENT; THROMBOCYTE CONCENTRATE;

ACUTE LYMPHOCYTIC LEUKEMIA; ADULT; AGED; ANTIBIOTIC SENSITIVITY; APHERESIS; ARTICLE; BLOOD TRANSFUSION; CASE REPORT; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; ECONOMIC ASPECT; FEMALE; FUNCTIONAL ASSESSMENT; GAMMA IRRADIATION; HEALTH CARE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HIP ARTHROPLASTY; HUMAN; HUMAN T CELL LEUKEMIA VIRUS 1; MALE; MEDICAL ASSESSMENT; MEDICAL LITERATURE; MEDLINE; NONHODGKIN LYMPHOMA; PATHOGENESIS; PUBLICATION; RISK FACTOR; SCHOOL CHILD; THROMBOCYTE; TREATMENT OUTCOME; UNITED STATES; VIRUS TRANSMISSION;

EID: 0142012106     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(03)80288-6     Document Type: Article

References (80)

1. Dodd RY. The safety of the blood supply: Current concepts. In: Hillyer CD, ed. The Safety of the Blood Supply: The Fenwal Monograph Series. Deerfield, I: Baxter Healthcare Corporation; 199;1-17.
2. Dow BC, Peterkin MA, Green RH, Cameron SO. Hepatitis B virus transmission by blood donation negative for hepatitis B surface antigen, antibody to HBsAg, antibody to hepatitis B core antigen and HBV DNA. Vox Sang. 2001;81:140. Letter.
3. Dodd RY, Notari EP, Stramer SL. Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population. Transfusion. 2002;42:975-979.
4. Schuttler CG, Caspari G, Jursch CA, et al. Hepatitis C virus transmission by a blood donation negative in nucleic acid amplification tests for viral RNA. Lancet. 2000;355: 41-42. Letter.
5. Blajchman MA, Goldman M. Bacterial contamination of platelet concentrates: Incidence, significance, and prevention. Semin Hematol. 2001;38(Suppl 11):20-26.
6. Kuehnert MJ, Roth VR, Haley NR, et al. Transfusion-transmitted bacterial infection in the United States, 1998 through 2000. Transfusion. 2001;41:1493-1499.
7. Ness P, Braine H, King K, et al. Single-donor platelets reduce the risk of septic platelet transfusion reactions. Transfusion. 2001;41:857-861.
8. Perez P, Salmi LR, Follea G, et al. Determinants of transfusion-associated bacterial contamination: Results of the French BACTHEM Case-Control Study. Transfusion. 2001;41:862-872.
9. Barbara J. The rationale for pathogen inactivation treatment of platelet components - introduction. Semin Hematol. 2001;38(Suppl 11):1-3.
10. Grass JA, Wafa T, Reames A, et al. Prevention of transfusion-associated graft-versus-host disease by photochemical treatment. Blood. 1999;93:3140-3147.
11. Knutson F, Alfonso R, Dupuis K, et al. Photochemical inactivation of bacteria and HIV in buffy-coat-derived platelet concentrates under conditions that preserve in vitro platelet function. Vox Sang. 2000;78:209-216.
12. Rios J, Hambleton J, Viele M, et al. Helinx treated RBC transfusions are well tolerated and show comparable recovery and survival to control RBCs. Presented at: 54th Annual Meeting of the American Association of Blood Banks; October 13-17, 2001; San Antonio, Tex.
13. deAlarcon P, Benjamin R, Shopnick R, et al. Hemostatic response in congenital coagulation factor-deficient patients transfused with fresh frozen plasma (FFP) prepared by Helinx pathogen inactivation technology - The Step CC Trials. Presented at: 54th Annual Meeting of the American Association of Blood Banks, October 13-17, 2001; San Antonio, Tex.
14. Drummond MF, O'Brien B, Stoddart GL, et al. Methods for the Economic Evaluation of Health Care Programmes. 2nd ed. New York: Oxford University Press; 1997.
15. Lopez-Plaza I, Weissfeld J, Triulzi DJ. The cost-effectiveness of reducing donor exposures with single-donor versus pooled random-donor platelets. Transfusion. 1999;39:925-932.
16. HCUPnet. Healthcare Cost and Utilization Project Web site. Available at: http://hcup. ahrq.gov/HCUPnet.asp. Accessed April 10, 2003.
17. Blood Products Usage Summary 2002. Rockville, Md: InforMedix Marketing Research, Inc; 2002.
18. Meehan KR, Matias CO, Rathore SS, et al. Platelet transfusions: Utilization and associated costs in a tertiary care hospital. Am J Hematol. 2000;64:251-256.
19. Garellick G, Malchau H, Herberts P, et al. Life expectancy and cost utility after total hip replacement. Clin Orthop. 1998;346:141-151.
20. Dearborn JT, Harris WH. Postoperative mortality after total hip arthroplasty. An analysis of deaths after two thousand seven hundred and thirty-six procedures. J Bone Joint Surg Am. 1998;80:1291-1294.
21. Berg S, Steuber P, Poplack D. Clinical manifestations of acute lymphoblastic leukemia. In: Huffman R, Benz E Jr, Shattil SJ, et al, eds. Hematology, Basic Principles and Practice. New York: Churchill Livingstone; 2000:1070-1078.
22. Bhatia S, Sather HN, Pabustan OB, et al. Low incidence of second neoplasms among children diagnosed with acute lymphoblastic leukemia after 1983. Blood. 2002;99:4257-4264.
23. Tengs TO, Wallace A. One thousand health-related quality-of-life estimates. Med Care. 2000;38:583-637.
24. Beck JR, Kassirer JP, Pauker SG. A convenient approximation of life expectancy (the "DEALE"). I. Validation of the method. Am J Med. 1982;73:883-888.
25. Beck JR, Pauker SG, Gottlieb JE, et al. A convenient approximation of life expectancy (the "DEALE"). II. Use in medical decision-making. Am J Med. 1982;73:889-897.
26. Brecher ME, Means N, Jere CS, et al. Evaluation of an automated culture system for detecting bacterial contamination of platelets: An analysis with 15 contaminating organisms. Transfusion. 2001;41:477-482.
27. Blood Products Advisory Committee 76th Meeting Minutes. Rockville, Md: US Dept of Health and Human Services, Food and Drug Administration Center for Biologics Evaluation and Research; 2003.
28. Trivedi M, Newly diagnosed hepatitis C. Lack of symptoms doesn't mean lack of progression. Postgrad Med. 1997;102:95-98, 101.
29. Muir AJ. The natural history of hepatitis C viral infection. Semin Gastrointest Dis. 2000;11:54-61.
30. Birkmeyer JD, AuBuchon JP, Littenberg B, et al. Cost-effectiveness of preoperative autologous donation in coronary artery bypass grafting. Ann Thorac Surg. 1994;57:161-168.
31. National Center for Infectious Diseases. Viral hepatitis B. Available at: http://www.cdc.gov/ ncidod/diseases/hepatitis/b/index.htm. Accessed January 8, 2003.
32. Wong JB, Poynard T, Ling MH, et al. Cost-effectiveness of 24 or 48 weeks of interferon alpha-2b alone or with ribavirin as initial treatment of chronic hepatitis C. International Hepatitis Interventional Therapy Group. Am J Gastroenterol. 2000;95:1524-1530.
33. Theodore D, Fried MW. Natural history and disease manifestations of hepatitis C infection. Curr Top Microbiol Immunol. 2000;242:43-54.
34. Singer ME, Younossi ZM. Cost effectiveness of screening for hepatitis C virus in asymptomatic, average-risk adults. Am J Med. 2001;111:614-621.
35. Lam NP. Hepatitis C: Natural history, diagnosis, and management. Am J Health Syst Pharm. 1999;56:961-973.
36. Satoor S, Raufman JP. Treatment of hepatitis C. Clin Cornerstone. 2001;3:37-46.
37. Dienstag JL, Isselbacher KJ. Acute viral hepatitis. In: Braunwald E, Fauci AS, Kasper DL, et al, eds. Harrison's Principles of Internal Medicine. 15th ed. New York: McGraw-Hill; 2001:1721-1742.
38. Owens DK, Nease RF Jr. Occupational exposure to human immunodeficiency virus and hepatitis B virus: A comparative analysis of risk. Am J Med. 1992;92:503-512.
39. Etchason J, Petz L, Keeler E, et al. The cost effectiveness of preoperative autologous blood donations. N Engl J Med. 1995;332:719-724.
40. Roback JD, Hillyer CD. The role of leukocyte reduction in minimizing the risk of transfusion-transmission of cell-associated infectious agents and immunomodulation. In: Hillyer CD, ed. The Safety of the Blood Supply: The Fenwal Monograph Series. Deerfield, Ill: Baxter Healthcare Corporation; 1999:28-45.
41. Ohlen J, Liegl JM, Selmair H. Long-term prognosis of chronic B and C viral hepatitis [in German]. Leber Magen Darm. 1995;25:205-210.
42. Kim WR, Poterucha JJ, Hermans JE, et al. Cost-effectiveness of 6 and 12 months of interferon-alpha therapy for chronic hepatitis C. Ann Intern Med. 1997;127:866-874.
43. Younossi ZM, Singer ME, McHutchison JG, Shermock KM. Cost effectiveness of interferon alpha2b combined with ribavirin for the treatment of chronic hepatitis C. Hepatology. 1999;30:1318-1324.
44. Bennett WG, Inoue Y, Beck JR, et al. Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C. Ann Intern Med. 1997;127:855-865.
45. Bayoumi AM, Redelmeier DA. Economic methods for measuring the quality of life associated with HIV infection. Qual Life Res. 1999;8:471-480.
46. Patil R, Cotler SJ, Banaad-Omiotek G, et al. Physicians' preference values for hepatitis C health states and antiviral therapy: A survey. BMC Gastroenterol. 2001;1:6.
47. Stigum H, Magnus P, Samdal HH, Nord E. Human T-cell lymphotropic virus testing of blood donors in Norway: A cost-effect model. Int J Epidemiol 2000;29:1076-1084.
48. American Red Cross. Hospital Information: Reimbursement. Available at: http://www. redcrosslife.org/hospital/hos_reimbursement.asp. Accessed January 14, 2003.
49. Financial impact of technologies to improve blood safety. Testimony by America's Blood Centers before Medicare Payment Advisory Commission. Available at: http:// www.americasblood.org/index.cfm?fuseaction=Display.showPage& pageid=61. Accessed February 6, 2003.
50. Bozzette SA, Berry SH, Duan N, et al. The care of HIV-infected adults in the United States. HIV Cost and Services Utilization Study Consortium. N Engl J Med. 1998;339: 1897-1904.
51. AuBuchon JP, Birkmeyer JD, Busch MP. Cost-effectiveness of expanded human immunodeficiency virus-testing protocols for donated blood. Transfusion. 1997;37:45-51.
52. Hart AC, Richards B, eds. DRG Guidebook. 17th ed. Reston, Va: St. Anthony Publishing; 2000.
53. Solheim BG, Wesenberg F. Rational use of blood products. Eur J Cancer. 2001;37: 2421-2425.
54. Zeger G, Williams CT, Shulman IA. Single donor platelets: Can we afford to use them? Can we afford not to use them? Transfus Sci. 1997;18:585-588.
55. Guidance for Industry: Gamma Irradiation of Blood and Blood Components: A Pilot Program for Licensing. Rockville, Md: US Dept of Health and Human Services, Food and Drug Administration Center for Biologics Evaluation and Research; 2000.
56. The future use of pathogen-inactivated platelet concentrates. Vox Sang. 2003;85:54-66.
57. List of ambulatory payment classifications (APCs) with status indicators, relative weights, payment rates, and copayment amounts calendar year 2002. 66 Federal Register 44726 (2001).
58. Solberg CO. Microorganisms strike back - Infectious diseases during the last 50 years [in Norwegian]. Tidsskr Nor Laegeforen. 2001;121:3538-3543.
59. Hepatitis C: An emerging threat to public health. US Department of Health and Human Services Web site. Available at: www.hhs.gov/news/press/2001pres/01fshepatitisC.html. Accessed February 14, 2003.
60. Donahue JG, Munoz A, Ness PM, et al. The declining risk of post-transfusion hepatitis C virus infection. N Engl J Med. 1992;327:369-373.
61. McCullough J, Vesole D, Benjamin RJ, et al. Pathogen inactivated platelets (plt) using Helinx technology (INTERCEPT plt) are hemostatically effective in thrombocytopenic patients (tcp plts): The SPRINT trial. Blood. 2001;98:450a. Abstract.
62. van Rhenen D, Gulliksson H, Pamphilon D, et al. S-59 (Helinx) photochemically treated platelets (plt) are safe and effective for support of thrombocytopenia: Results of the EuroSPRITE phase 3 trial. Blood. 2000;96:823a. Abstract.
63. van Hout BA, Al MJ, Gordon GS, Rutten FF. Costs, effects and C/E-ratios alongside a clinical trial. Health Econ. 1994;3:309-319.
64. Hirth RA, Chernew ME, Miller E, et al. Willingness to pay for a quality-adjusted life year: In search of a standard. Med Decis Making. 2000;20:332-342.
65. Jackson BR, Busch MP, Stramer SL, AuBuchon JP. The cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations. Transfusion. 2003;43:721-729.
66. Stone PW, Teutsch S, Chapman RH, et al. Cost-utility analyses of clinical preventive services: Published ratios, 1976-1997. Am J Prev Med. 2000;19:15-23.
67. AuBuchon JP, Birkmeyer JD. Safety and cost-effectiveness of solvent-detergent-treated plasma. In search of a zero-risk blood supply. JAMA. 1994;272:1210-1214.
68. Pereira A, Sanz C. A model of the health and economic impact of posttransfusion hepatitis C: Application to cost-effectiveness analysis of further expansion of HCV screening protocols. Transfusion. 2000;40:1182-1191.
69. Pereira A. Cost-effectiveness of transfusing virus-inactivated plasma instead of standard plasma. Transfusion. 1999;39:479-487.
70. Yeh JM, Botteman M, Pashos CL, et al. Economics of transfusion. Infusionsther Transfusionsmed. 2002;29:218-225.
71. Loubiere S, Rotily M, Durand-Zaleski I, et al. Adjunction of polymerase chain reaction in screening for hepatitis C virus RNA in blood donations: Misuse of the principle of caution. Hypotheses Debats. 2001;17:344-349.
72. Simmonds P, Kurtz J, Tedder RS. The UK blood transfusion service: Over a (patent) barrel? Lancet. 2002;359:1713-1714.
73. Grima DT, Marshall D, Weinstein M, et al. Cost-effectiveness of screening donated blood with minipool nucleic acid testing for hepB virus, hepatitisC virus, and HIV. Value Health. 2002;5:446. Abstract.
74. van Hulst M, de Wolf JT, Staginnus U, et al. Pharmaco-economics of blood transfusion safety: Review of the available evidence. Vox Sang. 2002;83:146-155.
75. Sibrowski W, Penner M, Kuhnl P. Transfusion-induced virus infections: How great is the risk? [in German]. Infusionsther Transfusionsmed. 1993;20(Suppl 2):4-9.
76. Roth VR, Kuehnert MJ, Haley NR, et al. Evaluation of a reporting system for bacterial contamination of blood components in the United States. Transfusion. 2001;41:1486-1492.
77. Workshop on bacterial contamination of platelets - 9/24/1999. US Food and Drug Administration Web site. Available at: http://www.fda.gov/cber/minutes/workshop-min.htm. Accessed November 21, 2002.
78. Seeff LB. Why is there such difficulty in defining the natural history of hepatitis C? Transfusion. 2000;40:1161-1164.
79. New data show that INTERCEPT Blood System inactivates virus in same viral family as SARS [press release]. Madrid, Spain: Baxter Healthcare Corporation; June 17, 2003.
80. Dupuis K, Alfonso R, Savoor A, et al. Helinx Technology, used in the Intercept Blood System, inactivates high titers of emerging insect-borne pathogens in platelets and red blood cells. Abstract presented at: VIII International Society of Blood Transfusion Regional European Congress; July 5-9, 2003; Istanbul, Turkey.